Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 1, 2025European Journal of NeurologyOpen Access

Recent Advances in Interventions Targeting Remyelination and a Systematic Review of Remyelinating Effects of Approved Disease‐Modifying Treatments for Multiple Sclerosis

View Full Paper
Ask AI
Bookmark
Share

Authors

AKAnna-Victoria De KeersmaeckerEDEline Van DoninckIWInez Wens

Discussion

Loading...

Member takes

Overview

Systematic review reports neuroprotective properties and remyelination potential of glatiramer acetate in multiple sclerosis, suggesting new therapeutic combinations.

Key Points

  • The aim is to evaluate disease-modifying treatments with remyelinating effects for multiple sclerosis.
  • Systematic review of preclinical and clinical studies
  • Analysis of articles and trials on remyelination
  • Assessment of FDA and EMA-approved treatments
  • Preclinical studies indicate neuroprotective properties of treatments
  • Clinical trials show potential of glatiramer acetate for remyelination
  • Insufficient evidence to attribute surrogate marker changes solely to remyelination

Cite This Study

Keersmaecker et al. (2025) studied this question.

synapsesocial.com/papers/6925435ec0ce034ddc35817ehttps://doi.org/10.1111/ene.70397
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The Road to Remyelination in Multiple Sclerosis: Breakthroughs, Challenges, and Considerations for Future Trial Design2025 · 14 citations
  2. 2Investigational approaches to multiple sclerosis therapy.2026 · 1 citations
  3. 3Therapeutic strategies in multiple sclerosis: a systematic review of current and emerging approaches2026 · 1 citations
  4. 4Adjunctive Non-Disease-Modifying Therapies in Multiple Sclerosis: Immunometabolic, Neuroprotective and Remyelination-Oriented Approaches2026
  5. 5Myelin Repair as a Neuroprotective Strategy for Multiple Sclerosis: From Bench to Bedside2026